Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress - PubMed (original) (raw)
Review
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress
Paul Workman et al. Ann N Y Acad Sci. 2007 Oct.
Abstract
The molecular chaperone HSP90 has emerged as an exciting target for cancer treatment. We review the potential advantages of HSP90 inhibitors, particularly the simultaneous combinatorial depletion of multiple oncogenic "client" proteins, leading to blockade of many cancer-causing pathways and the antagonism of all of the hallmark pathological traits of malignancy. Cancer selectivity is achieved by exploiting cancer "dependencies," including oncogene addiction and the stressed state of malignant cells. The multiple downstream effects of HSP90 inhibitors should make the development of resistance more difficult than with agents having more restricted effects. We review the various classes of HSP90 inhibitor that have been developed, including the natural products geldanamycin and radicicol and also the purine scaffold and pyrazole/isoxazole class of synthetic small molecule inhibitors. A first-in-class HSP90 drug, the geldanamycin analog 17-AAG, has provided proof of concept for HSP90 inhibition in patients at well tolerated doses and therapeutic activity has been seen. Other inhibitors show promise in preclinical and clinical development. Opportunities and challenges for HSP90 inhibitors are discussed, including use in combination with other agents. Most of the current HSP90 inhibitors act by blocking the essential nucleotide binding and ATPase activity required for chaperone function. Potential new approaches are discussed, for example, interference with cochaperone binding and function in the superchaperone complex. Biomarkers for use with HSP90 inhibitors are described. We stress how basic and translational research has been mutually beneficial and indicate future directions to enhance our understanding of molecular chaperones and their exploitation in cancer and other diseases.
Similar articles
- Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone.
Workman P. Workman P. Cancer Lett. 2004 Apr 8;206(2):149-57. doi: 10.1016/j.canlet.2003.08.032. Cancer Lett. 2004. PMID: 15013520 Review. - The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P. Workman P. Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. doi: 10.1007/s00280-003-0593-0. Epub 2003 Jun 18. Cancer Chemother Pharmacol. 2003. PMID: 12819933 Review. - Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
Powers MV, Workman P. Powers MV, et al. Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35. doi: 10.1677/erc.1.01324. Endocr Relat Cancer. 2006. PMID: 17259553 Review. - High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity.
Rowlands MG, Newbatt YM, Prodromou C, Pearl LH, Workman P, Aherne W. Rowlands MG, et al. Anal Biochem. 2004 Apr 15;327(2):176-83. doi: 10.1016/j.ab.2003.10.038. Anal Biochem. 2004. PMID: 15051534 - Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90.
Koga F, Kihara K, Neckers L. Koga F, et al. Anticancer Res. 2009 Mar;29(3):797-807. Anticancer Res. 2009. PMID: 19414312 Review.
Cited by
- Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y. Ono N, et al. Cancer Sci. 2013 Oct;104(10):1346-52. doi: 10.1111/cas.12237. Epub 2013 Aug 20. Cancer Sci. 2013. PMID: 23863134 Free PMC article. - Androgen Receptor in Hormone Receptor-Positive Breast Cancer.
Khan AF, Karami S, Peidl AS, Waiters KD, Babajide MF, Bawa-Khalfe T. Khan AF, et al. Int J Mol Sci. 2023 Dec 29;25(1):476. doi: 10.3390/ijms25010476. Int J Mol Sci. 2023. PMID: 38203649 Free PMC article. Review. - Heat shock protein 90 inhibition: rationale and clinical potential.
Den RB, Lu B. Den RB, et al. Ther Adv Med Oncol. 2012 Jul;4(4):211-8. doi: 10.1177/1758834012445574. Ther Adv Med Oncol. 2012. PMID: 22754594 Free PMC article. - Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum W. Walker AR, et al. Leuk Lymphoma. 2013 Sep;54(9):1996-2002. doi: 10.3109/10428194.2012.760733. Epub 2013 Jan 24. Leuk Lymphoma. 2013. PMID: 23256542 Free PMC article. Clinical Trial. - Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas.
Schwartz H, Scroggins B, Zuehlke A, Kijima T, Beebe K, Mishra A, Neckers L, Prince T. Schwartz H, et al. Cell Stress Chaperones. 2015 Sep;20(5):729-41. doi: 10.1007/s12192-015-0604-1. Epub 2015 Jun 13. Cell Stress Chaperones. 2015. PMID: 26070366 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources